Paroxysmal supraventricular tachycardia (PSVT)

Abrupt SVT episodes commonly lead to palpitations, shortness of breath, chest pressure, lightheadedness, fatigue and anxiety. PSVT is caused by abnormal electrical connections in the heart that cause irregular contraction.

Approximately 2.3-4 in 1,000 people have PSVT, resulting in an estimated overall patient population of 3-6 million in China. Current treatments for termination of acute episodes require emergency setting administration of IV calcium channel blockers and IV antiarrhythmics. Patients typically have multiple, unpredictable PSVT episodes per year, leading to a significant impact on their quality of life. 

Etripamil nasal spray is a disruptive calcium channel blocker designed to keep patients out of the emergency room (ER) and operating room (OR). Etripamil can be self-administered, enabling a convenient and effective rapid treatment outside of the hospital setting. Etripamil is positioned to significantly alter the acute treatment of PSVT, allowing patients to quickly terminate episodes without the fear or inconvenience of having to rush to the hospital for treatment.

CORXEL acquired the Greater China right with etripamil in May 2021 from Milestone Pharmaceuticals. In October 2023, Milestone announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). In September 2024, JIXING announced positive results from Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with paroxysmal supraventricular tachycardia.

Reference: 

• Chiang JK, Kao HH, Kao YH. Association of Paroxysmal Supraventricular Tachycardia with Ischemic Stroke: A National Case-Control Study. Journal of Stroke and Cerebrovascular Diseases (2017); 26(7):1493-1499.

• Chan CL, Li AA, Chung HA, Phan DV. Cost Effectiveness Analysis and Payment Policy Recommendation-Population-Based Survey with Big Data Methodology for Readmission Prevention of Patients with Paroxysmal Supraventricular Tachycardia treated with Radiofrequency Catheter Ablation. International Journal of Environmental Research and Public Health (2020); 17(7):2334.

• Ho HH, Yeh SJ, Tsai WP, et al. Paroxysmal supraventricular tachycardia and Wolff-Parkinson-White syndrome in ankylosing spondylitis: a large cohort observation study and literature review. Seminars in Arthritis and Rheumatism (2012); 42(3):246-53.

• Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. Journal of the American College of Cardiology (1998); 31(1):150-7.